Since prostate cancer appears to be uniquely deficient in the phase 2 enzyme GSTP1, a rational prevention strategy might be to compensate for GSTP1 loss by global induction of phase 2 enzymes within the prostate. The gene discussed is GSTP1; the disease is prostate cancer.